Liver cancer approval brings some redemption for forgotten AstraZeneca asset
It was more than five years ago that AstraZeneca (LSE: AZN) announced disappointing Phase III progression-free survival results from its MYSTIC lung cancer trial of Imfinzi (durvalumab) monotherapy or in combination with tremelimumab.
The study was billed as crucial for AstraZeneca’s prospects at the time, and the results sent shares tumbling by 16%, despite management’s protestations that it really was not as big a deal as investors seemed to think.
"With this first regulatory approval for Imjudo, patients now have an approved dual immunotherapy treatment regimen that harnesses the potential of CTLA-4 inhibition in a unique combination with a PD-L1 inhibitor"In this instance, management turned out to be right. AstraZeneca has had a strong few years since, with approvals and healthy sales from Tagrisso (osimertinib), Lynparza (olaparib), the COVID-19 vaccine Vaxzevria and Imfinzi in other settings, as well as other progress, making MYSTIC feel like a long-forgotten relic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze